Combination therapy for HCC: from CRISPR screening to the design of clinical therapies

Combination therapy for HCC: from CRISPR screening to the design of clinical therapies

Bibliographic Details
Main Authors:	Yunguang Wang, Ling Kui, Guangchuan Wang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-10-01
Series:	Signal Transduction and Targeted Therapy
Online Access:	https://doi.org/10.1038/s41392-021-00775-1

Similar Items

Evaluation of HCC Screening Program with Abdominal Sonography for Subjects Identified from Their Family Index HCC Cases
by: Lei-Ling Wang, et al.
Published: (2009)

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
by: Laia Castells-Roca, et al.
Published: (2021-03-01)

Prospects and Challenges for T Cell-Based Therapies of HCC
by: Norman Woller, et al.
Published: (2021-06-01)

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
by: Lai Wei, et al.
Published: (2019-10-01)

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
by: Yawen Dong, et al.
Published: (2021-04-01)

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
by: Mubalake Abudoureyimu, et al.
Published: (2019-11-01)

Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC
by: Rahul Deshpande, et al.
Published: (2011-01-01)

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
by: Meiou Dai, et al.
Published: (2021-05-01)

Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy
by: Michael Y. He, et al.
Published: (2021-07-01)

Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)
by: Pedro Viveiros, et al.
Published: (2019-07-01)

Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
by: Mubalake Abudoureyimu, et al.
Published: (2020-05-01)

Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting
by: Maria Cristina Bonferoni, et al.
Published: (2020-04-01)

Cancer Stem Cells: A Potential Breakthrough in HCC-Targeted Therapy
by: Yafei Wu, et al.
Published: (2020-03-01)

358 Trial in progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC)
by: Peter Doran, et al.
Published: (2020-11-01)

Design of time-delayed safety switches for CRISPR gene therapy
by: Dashan Sun
Published: (2021-08-01)

Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic
by: Dianne Nicol, et al.
Published: (2017-09-01)

Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders
by: Fai-Meng Sou, et al.
Published: (2019-01-01)

Insights of HBV Pathogenesis and Emerging Clinical Therapies for HBV Induced HCC Patients for a Better Prognostic Outcome
by: Reshmi Chatterjee
Published: (2015-02-01)

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
by: Saieh Hajighasemlou, et al.
Published: (2020-01-01)

Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy
by: Rosanna Villani, et al.
Published: (2018-12-01)

Suitability of the woodchuck HCC as a preclinical model for evaluation of intra‐arterial therapies
by: Alexander Y. Kim, et al.
Published: (2020-03-01)

Développement de nouveaux nanovecteurs pour les thérapies anti-HCV/HCC
by: Alles, Roxane
Published: (2013)

SHP-1/STAT3-related signaling pathway in HCC targeting therapy
by: Wei-Tien Tai, et al.
Published: (2012)

Développement de nouveaux nanovecteurs pour les thérapies anti-HCV/HCC
by: Alles, Roxane
Published: (2013)

Status of, and strategies for improving, adherence to HCC screening and surveillance
by: Francica G, et al.
Published: (2019-07-01)

Establishment of Anti-HCC Drug Screening Platform in Zebrafish
by: 林涵軒
Published: (2014)

CRISPR-FOCUS: A web server for designing focused CRISPR screening experiments.
by: Qingyi Cao, et al.
Published: (2017-01-01)

Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites
by: Huzheng Yan, et al.
Published: (2020-12-01)

AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy
by: Takao Watanabe, et al.
Published: (2021-06-01)

Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients
by: Ron C. Gaba, et al.
Published: (2013-09-01)

The Effects of Liver Cancer-Specific Gene Therapy on HCC Cells Expressing HBx Protein
by: Yu-Chien Peng, et al.
Published: (2014)

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
by: I. А. Dzhanyan, et al.
Published: (2021-06-01)

Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design
by: Etienne Garin, et al.
Published: (2020-06-01)

Hemoglobinopathy correction with CRISPR or not; gene therapy is the solution
by: Bader Al Alwan, et al.
Published: (2020-01-01)

The Impact of CRISPR-Cas System on Antiviral Therapy
by: Hadi Bayat, et al.
Published: (2018-11-01)

CRISPR technology: The engine that drives cancer therapy
by: Mingtao Zhang, et al.
Published: (2021-01-01)

HCC screening: assessment of an abbreviated non-contrast MRI protocol
by: Michael Vinchill Chan, et al.
Published: (2019-12-01)

CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
by: Wei-Jing Dai, et al.
Published: (2016-01-01)

HCC Heterogeneity: Molecular Pathogenesis and Clinical Implications
by: Emilia Fransvea, et al.
Published: (2009-01-01)